Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Windham-Bannister Susan RichardsOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Satz BrianOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Kisner Daniel LOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Jackson JonathanOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Fuhrmann RochelleOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Crean David HughOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
Filings by filing date
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Windham-Bannister Susan RichardsOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Satz BrianOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Kisner Daniel LOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Jackson JonathanOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Fuhrmann RochelleOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
-
Jun 20, 2023 (filed on Jun 21, 2023)Insider Name:Crean David HughOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:6,835Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10655 SORRENTO VALLEY ROAD, SUITE 200 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://histogen.com |
IR: | See website |
Key People | ||
Susan A. Knudson President, Chief Executive Officer, Chief Financial Officer |
Business Overview |
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases. |
Financial Overview |
For the nine months ended 30 September 2023, Histogen Inc revenues decreased 100% to $15K. Net loss applicable to common stockholders increased 16% to $9.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase of 7% to $416K (expense), Stock-based Compensation in R&D increase of 22% to $28K (expense). |
Employees: | 7 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.02M as of Sep 30, 2023 |
EBITDA (TTM): | -$11.92M as of Sep 30, 2023 |
Net annual income (TTM): | -$12.38M as of Sep 30, 2023 |
Free cash flow (TTM): | -$10.08M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 4,271,759 as of Nov 9, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |